Eisai Co., Ltd.

8月12日，知名治疗阿尔兹海默症（AD）药物，甘露特纳胶囊（俗称971胶囊）被下发了通知件，依据受理号推断，应当是附条件审批转常规审批失败。 相关文章：绿谷制药971，再注册失败！ 这款治疗阿尔茨海默病的争议性药物正式退出市场，而失败原因推测是IV期临床试验结果不佳。 971胶囊无了，那么其他治疗AD的药物，还有么？ ↓ 扫码加入药通社交流群 ↓ 971无了，还有中药！ 6月18日，华西医院招募阿尔茨海默症的中药创新药KH110（五加益智颗粒）临床III期受试者的消息传来，诸多患者要求入组参与试验。 图源：药圈观察局 相较于昂贵的单抗治疗，中药治疗AD，或许是新方法？ 事实上，国内一些中药创新药先驱企业早已开始行动。 首先是上文提到的，康弘药业旗下四川济生堂自主研发的KH110（五加益智颗粒），现已进入临床III期。 该药用于脾肾两虚所致痴呆，适用于轻、中度AD患者。主要疗效指标为治疗12个月后，与安慰剂组阿尔茨海默病评定量表-认知部分（ADAS-cog/12）评分及临床痴呆评定量表（CDR-SB）较基线改变的组间差异。 与此同时，康缘医药正在进行苁蓉总苷胶囊治疗轻中度AD（髓海不足证）Ⅱ期临床试验。 首例受试者已于2025年4月14日签署知情同意书，计划入组136例，主要评估阿尔茨海默病评价量表-认知子量表（ADAS-cog/11）认知评分变化及不良事件，评价周期为用药前至用药后24周。 除此之外，北京恒清堂医药也在进行参芪醒脑颗粒治疗轻度阿尔茨海默病的Ⅱ期临床研究。 主要终点为36周治疗结束后阿尔茨海默病评价量表-认知部分（ADAS-Cog）评分变化，目标入组160人，目前已完成入组。 这之中，进度最快的是四川济生堂。时间分析，如果临床试验顺利，最早2026年底能有III期临床试验数据。预计完成临床之后，就会提交上市。 这么看来，未来中药治AD或真将成为可能？ 放眼全球，AD市场到底有多庞大？ 答案是：平均每3秒增加1例患者。 据WHO数据，2023年全球 AD 患者已超 5500 万，预计2050 年将增至 1.39 亿，每3秒就会增加1例患者。而中国是全球 AD 患者最多的国家。 据中国阿尔茨海默病协会（ADC）2023 年统计，我国 AD 患者约 983 万，预计 2030 年将突破 1900 万。 正因如此，AD庞大的患病人群吸引着各大企业争相研发，但结果却一言难尽。 2012年，强生/辉瑞的单抗药物Bapineuzumab的III期临床试验失败； 2014年，罗氏宣告Gantenerumab的III期临床试验失败； 2016年，礼来宣告III期临床药物Solanezumab没有达到主要临床终点； 2017年，默沙东宣布停止开发BACE抑制剂药物Verubecestat； 2018年，强生宣布其终止了BACE抑制剂剂Atabecestat II/III期临床试验...... 最接近成功的一次，是2021年6月，FDA批准卫材和渤健共同研发的Aduhelm终于成功上市，那是第一款基于Aβ级联的药物，也是第一款治疗AD本身的药物。 然而虽然Aduhelm在美国顶着腥风血雨上市了，但因其存在明显副作用，且价格极其昂贵（年治疗费高达5.8万美金），上市后难以推广，最终卫材和渤健选择停止了Aduhelm的商业化进程。 失败案例不胜枚举，也因此，阿尔茨海默病的新药研发被行业称作“地狱级”挑战，甚至被业内形容为“死亡之谷”，失败率高达99.6％。 市场如此庞大，研发了这么多年，但AD治疗药物依然寥寥可数。 截至目前，能够同时被美、欧、日、中多国所认可的早期AD治疗药物，却只有两款：一款是卫材和渤健的仑卡奈单抗；另一款是礼来的多奈单抗。 2023年1月，还是卫材和渤健，首次Aduhelm的研发成功让他们找到了AD药物的研究路径，也就是目前最被大众认可的基于淀粉样蛋白假说的研发路径。 基于Aduhelm的经验，终于开发出了首款FDA完全批准的Aβ单抗药物（仑卡奈单抗），用于治疗早期AD患者，成为全球首个能延缓AD进程的药物。 2024年7月，礼来上市了第二款Aβ单抗药物，多奈单抗，一经上市就备受质疑，据实验数据显示多奈单抗副作用发生几率远高于仑卡奈单抗，今年7月，礼来更新了多奈单抗的给药方式，可有效降低副作用发生率。 质疑声逐渐变小，但这两款药物还有一个最大的问题：治疗费用过于昂贵，在国内两款药都不进医保，对患者及其家属来说负担太重。 过高价格导致这两款药在上市起质疑声就不断，且仑卡奈单抗和多奈单抗仅适用于早期AD患者，对于中、重度AD治疗依旧束手无策。 AD药物，各有各的难，未来之路，任重而道远！或许真的靠中药了？ 参考： [1]医耀—阿尔兹海默病走出“技术沉没周期” [2]药圈观察局—中药AD新药，已进入临床III期 [3]中种看药—阿尔茨海默病新药研发进展及康缘药业所处位置 本文截图均来自：摩熵医药 ↓关注药通社，洞见行业趋势↓ 投稿/企业合作/内容沟通： 药通社总编—华籍美人（Ww_150525） *添加请注明企业及来意

1.黑龙江召开药品流通监管暨药品经营环节“清源”行动现场推进会 近日，黑龙江省药品流通监管暨药品经营环节“清源”行动现场推进会在七台河市勃利县召开。会议聚焦药品流通领域突出问题，通过实地观摩、深入交流、总结经验，系统部署下一阶段攻坚任务。省药监局党组书记、局长李劲松出席会议并讲话，七台河市副市长夏文飞致辞。 与会代表首先深入勃利县医疗机构、零售终端和监管一线开展专项观摩。在勃利县人民医院，重点查看药品追溯系统应用、特殊药品管理制度落实情况，以及药品不良反应监测工作成效；在基层卫生院，实地观看疫苗监管情况；在政务服务中心，观摩药品经营许可审批流程优化成果；在连锁药店和批发企业，重点观看“龙江药品电子监管信息系统”应用，以及温控系统运行及票据管理规范落实情况。通过“走流程、看实况、查台账”的沉浸式观摩，与会人员对当地药品经营环节“清源”行动推进情况有了直观认知，并就发现的共性问题展开现场研讨。 在推进会上，哈尔滨市、齐齐哈尔市、佳木斯市、七台河市、大庆市大同区、绥化市绥棱县市场监管局及省药监局稽查三处，围绕药品经营环节“清源”行动阶段性成效、药品追溯体系建设等重点工作，交流了监管机制创新、跨部门联合执法、典型案件查办等方面的实践经验，充分展现了全省药监系统坚决贯彻落实党中央、国务院及省委、省政府决策部署的政治担当和合力攻坚态势。 会议强调，药品安全事关人民群众生命健康，事关经济社会发展大局，必须从拥护“两个确立”、做到“两个维护”的政治高度，深刻认识抓好药品流通监管的极端重要性，以“时时放心不下”的责任感打好监管攻坚战、持久战。要通过总结经验、剖析问题、凝聚共识，切实把思想和行动统一到党中央决策部署上来，把各方力量汇聚到破解监管难题、提升治理效能上来，确保药品经营环节“清源”行动取得实实在在的成效。 会议要求，要以药品经营环节“清源”行动为重要抓手，系统推进监管体系重塑，重点在全链条监管、智慧化治理、协同共治三大领域精准发力；严格压实属地管理责任、企业主体责任及从业者岗位责任，加快构建“政府主导、企业主责、行业自律、社会监督”的药品安全共治格局；健全风险防控、行刑衔接、舆情引导等长效机制，全面推进药品安全治理体系和治理能力现代化，为建设健康龙江提供坚强保障。 此次推进会通过“实地观摩找差距、集中研讨谋突破、系统部署抓落实”的工作机制，为纵深推进药品经营环节“清源”行动注入新动能，明确时限要求和责任主体，确保会议成果转化为治理效能。省药监局相关处室负责人、各市（地）市场监管局分管局领导及业务骨干等参会。 2.海南省药监局发布“清源”行动典型案例（第一期） 2025年4月以来，海南省药监局深入贯彻落实国家药监局和省委、省政府有关加强药品安全工作的决策部署，坚持高位推动，扎实推进药品安全“清源”行动开展。现将第一期“清源”行动典型案例公布如下： 案例一：海南某医药有限公司未遵守药品经营质量管理规范案 2025年4月，海南省药监局对海南某医药有限公司进行检查，发现该公司为避开集团对药品销售区域管控，在GSP计算机系统中虚构药品销售记录。该公司的行为属于未遵守药品经营质量管理规范情节严重的情形，违反了《中华人民共和国药品管理法》第五十三条第一款的规定。海南省药监局依据《中华人民共和国药品管理法》第一百二十六条的规定，给予该公司罚款50万元的行政处罚。 警示意义：《药品经营与使用质量监督管理办法》第六十九条第（三）项规定，药品经营质量管理和质量控制过程中，记录或者票据不真实，存在虚假欺骗行为的，药品监管部门可以依据《中华人民共和国药品管理法》第一百二十六条规定的情节严重的情形给予处罚。本案中的药品经营企业虚构药品销售记录的行为依法被认定属于未遵守药品经营质量管理规范情节严重的情形，从而受到处罚。该行为不仅扰乱了药品市场秩序，还破坏了公平竞争的市场环境。药品经营企业从事药品经营活动，应当遵守药品经营质量管理规范，做到记录或者票据真实、可追溯。 案例二：海口某药房有限公司未经药师或者药学技术人员审核销售处方药逾期不改正案 2025年5月，海口某药房有限公司因未经依法经过资格认定的药师或者其他药学技术人员审核处方销售处方药，被海口市市场监管局责令限期整改。2025年6月，该公司销售药品仍存在上述行为，逾期不改正。海口某药房有限公司违反了《药品经营和使用质量监督管理办法》第四十二条第（五）项的规定。海口市市场监管局依据《药品经营和使用质量监督管理办法》第七十二条的规定，给予该公司罚款1万元的行政处罚。 警示意义：相较于非处方药，处方药常用于治疗更严重或复杂疾病，药效更强，在使用中应严格按照处方执行。《药品经营和使用质量监督管理办法》第四十二条第五款规定：“药品零售企业营业时间内，依法经过资格认定的药师或者其他药学技术人员不在岗时，应当挂牌告知。未经依法经过资格认定的药师或者其他药学技术人员审核，不得销售处方药”。以上规定对零售企业的药品销售以及质量管理作了更细致、更严谨的要求，也一定程度保障了患者用药的安全性、有效性、合理性。 案例三：海南陵水某药品超市未从具有药品经营资格的企业购进药品案 陵水某药品超市通过在“药房网商城”的某大药房有限公司（经营方式：零售）购进药品并销售。该药品超市未从具有药品经营资格的企业购进药品的行为违反了《中华人民共和国药品管理法》第五十五条的规定。陵水县综合行政执法局依据《中华人民共和国药品管理法》第一百二十九条和第一百三十条的规定，给予该药品超市没收违法所得和罚款合计1万余元的行政处罚。 警示意义：《中华人民共和国药品管理法》第五十五条规定“药品上市许可持有人、药品生产企业、药品经营企业和医疗机构应当从药品上市许可持有人或者具有药品生产、经营资格的企业购进药品；但是，购进未实施审批管理的中药材除外”。《中华人民共和国药品管理法实施条例》第七十七条规定，药品批发企业是指将购进的药品销售给药品生产企业、药品经营企业、医疗机构的药品经营企业。药品零售企业是指将购进的药品直接销售给消费者的药品经营企业。药品零售企业无销售药品给其他药品经营企业和药品使用单位的经营资格。本案中的药品超市从无经营资格的企业购进药品进行销售，从而受到处罚。 3.太原市局组织药品流通领域第二轮交叉检查 为深化药品经营环节“清源”行动，集中治理中药饮片零售环节违法行为，规范中药饮片市场秩序，近日，太原市市场监管局在全市范围内组织开展药品流通领域第二轮交叉检查。 本次检查随机确定被检查企业，采取全域交叉、“四不两直”、飞行检查的方式进行，共出动检查人员40余人，对78家中药饮片零售企业实施精准检查。聚焦中药饮片零售环节系统性风险，严查中药饮片采购渠道、储存养护、处方审核等环节，重点打击非法购进、掺杂使假、生虫霉变、擅自代用处方所列药品等违法行为。 通过深入细致的现场检查和资料核查，共发现各类问题缺陷和风险隐患186项，涉及企业65家。主要集中在供应商资质管理不严、验收记录不规范、储存养护条件不达标、装斗清斗记录缺失或不全、中药饮片混放或串斗等方面。针对上述问题，责令企业限期整改，并将检查发现的10批问题中药饮片送至省检验检测中心检验，目前已收到5批次不合格报告，对涉及问题的4家企业全部立案查处。 此次交叉检查是提升药品监管能力、强化风险防控、保障公众用药安全的重要实践。通过异地交叉执法、飞行检查、协同联动的模式，有效打破了地域监管壁垒，提升了执法检查的公正性和震慑力，增强了药品监管系统协同作战能力，实现了“查处一例、警示一片、规范全域”的整治效果，有力推动全市药品零售企业中药饮片质量管理水平提升，为深化“清源”行动、净化药品市场环境奠定了坚实基础。 太原市局将延续深化交叉检查行动，持续跟踪问题整改和案件查办情况，进一步巩固交叉检查成果，规范中药饮片零售经营行为，切实防范化解药品安全风险，全力保障人民群众用药安全有效。 编辑：陈丽娜、张洁莹 版式编辑：于成林 审校：马飞、张松 赛诺菲回应波立达停供！恒瑞、康方、君实等围战PCSK9 2025医保商保初审名单透视：礼来、诺和诺德GLP-1混战，吉利德、科伦ADC交锋，卫材、BMS双线突围 专利纠纷和解！GSK分羹3.7亿美元，辉瑞/BioNTech认栽买单？ www.yyjjb.com.cn 洞悉行业趋势 长按关注医药经济报 《中国处方药》 学术公众号 聚焦药学学术和循证研究 长按关注中国处方药 《医药经济报》 终端公众号 记录药品终端产经大事件 长按关注21世纪药店

ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapiesMed (Cell Press) Publication with MD Anderson Collaboration highlights Plinabulin’s rapid dendritic cell activation in responding patients across eight cancer types who failed prior immunotherapySEED Therapeutics’ RBM39 degrader ST-01156 clears FDA IND and advances toward Phase 1 trialsNew SEED Therapeutics CFO and CBO Dr. Bill Desmarais brings over 20 years of biotech leadership experience to accelerate development FLORHAM PARK, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today reported Q2 2025 financial results alongside clinical and corporate milestones. “At the heart of BeyondSpring’s pipeline is Plinabulin, a first-in-class agent potentially redefining cancer treatment by harnessing the body’s own immune system,” said Dr. Lan Huang, Co-Founder, Chair, and CEO. “Plinabulin’s ability to mature dendritic cells in human studies, bridges innate and adaptive immunity, offering potentially new hope to the 60% of NSCLC patients whose disease progresses after checkpoint inhibitor therapy. In our global Phase 3 trial (Dublin-3, published in LANCET Respiratory Medicine), plinabulin and docetaxel combination compared to standard of care docetaxel alone, delivered durable survival benefits alongside reduced chemotherapy-induced neutropenia — a combination with strong potential to influence standards of care.” Dr. Huang added, “BeyondSpring’s impact extends beyond Plinabulin. As SEED Therapeutics’ (“SEED”) founding shareholder, BeyondSpring, along with cornerstone investors and research collaborators Eli Lilly and Eisai, has supported SEED’s pioneering work in targeted protein degradation. SEED’s oral RBM39 molecular glue degrader, ST-01156, recently received FDA clearance to enter clinical trials, targeting aggressive cancers including Ewing Sarcoma and KRAS-driven tumors, with U.S. leading cancer institutions driving development forward.” Key Milestones: ASCO 2025 Presentation on Plinabulin Effect in Re-sensitizing Tumors Progressed on Prior PD-1/L1 Inhibitors: New data from a phase 2 study evaluating pembrolizumab in combination with Plinabulin and docetaxel in metastatic NSCLC patients who progressed on prior PD-1/L1 inhibitors, showed encouraging efficacy and safety data. The combination demonstrated median progression-free survival (PFS) of 6.8 months, confirmed objective response rate (ORR) of 18.2%, duration of response (DOR) of 7.2 months, disease control rate (DCR) of 77%, and overall survival (OS) of 78% at 15 months.Med (Cell Press) Publication on Plinabulin Mechanism in Dendritic Cell Maturation in Human Studies with MD Anderson Collaboration: Plinabulin, when used in combination with radiation and a checkpoint inhibitor, rapidly induces dendritic cell (DC) maturation in multiple cancer types in patients who failed prior immunotherapy. The combination was associated with tumor responses across eight types of cancer in patients previously refractory to immune checkpoint inhibitor (ICI) therapy, including NSCLC, head and neck cancer, and Hodgkin lymphoma. The study reported an ORR of 23% and a DCR of 54%. Importantly, the research identified a potential predictive biomarker, baseline GEF-H1 immune signature, which may support patient selection and clinical response prediction.SEED’s IND Clearance from US FDA for Lead Oncology Asset RBM39 Degrader ST-01156: The U.S. Food and Drug Administration (FDA) cleared SEED’s Investigational New Drug (IND) application for ST-01156, a brain penetrant, novel orally administered molecular glue degrader targeting RBM39.AACR 2025 Presentation on SEED’s Two Key Preclinical Advancements: 1) ST-01156 demonstrated complete tumor regression in Ewing Sarcoma models, and its corresponding mechanism, and 2) a dual-degrader approach showed promising activity in KRAS G12D target degradation and KRAS G12D-driven tumors.SEED Strengthened Leadership: Dr. Bill Desmarais, Ph.D., MBA, joins SEED Therapeutics as CFO and Chief Business Officer, bringing two decades of leadership in finance, business development, and strategic expertise in biopharma and biotech. Second Quarter Financial Results1Continuing operations: Research and development (R&D) expenses were $1.0 million for the quarter ended June 30, 2025 compared to $0.8 million for the quarter ended June 30, 2024. The $0.2 million increase was primarily due to higher professional service fees in regulatory and CMC activities as well as increased costs for Plinabulin research.General and administrative (G&A) expenses were $0.9 million for the quarter ended June 30, 2025, compared to $1.8 million for the quarter ended June 30, 2024. The $0.9 million decrease was primarily due to lower professional service costs in consulting for business development initiatives, and lower salary expenses driven by decrease in administrative headcount. Net loss: $1.9 million for the quarter ended June 2025, compared to $2.7 million for the quarter ended June 2024Cash and cash equivalents: $9.5 million as of June 30, 2025, compared to $2.9 million as of December 2024 Discontinued operations: Net loss: $2.8 million for the quarter ended June 2025, compared to $1.4 million for the quarter ended June 2024Current assets: $15.7 million as of June 2025, compared to $25.3 million as of December 2024 Year to Date Financial Results1Continuing Operations: Research and development (R&D) expenses were $1.9 million for the six months ended June 30, 2025 compared to $1.6 million for the six months ended June 30, 2024. The $0.3 million increase was primarily due to higher professional service fees in regulatory and CMC activities as well as increased costs for Plinabulin research.General and administrative (G&A) expenses were $2.7 million for the six months ended June 30, 2025, compared to $3.1 million for the six months ended June 30, 2024. The $0.4 million decrease was primarily due to lower salary expenses resulting from decrease in administrative headcount, and lower company overhead expenses mainly due to decrease in investor relations services and D&O insurance related costs. Net loss: $4.5 million for the six months ended June 2025, compared to $4.7 million for the six months ended June 2024 Discontinued operations: Net income (loss): $1 million for the six months ended June 2025, compared to ($2.6 million) for the six months ended June 2024 Note 1: Accounting UpdateFollowing definitive agreements in January 2025 to sell the majority of its Series A-1 Preferred Shares in SEED Therapeutics, BeyondSpring now reports SEED’s financial results as discontinued operations under ASC 205-20. BeyondSpring currently owns approximately 40% of SEED and upon completion of the future sale transactions BeyondSpring would own approximately 14% of SEED’s outstanding shares. About BeyondSpringBeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin’s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. Learn more at beyondspringpharma.com. About SEED TherapeuticsSEED Therapeutics pioneers targeted protein degradation through novel molecular glues and bifunctional degraders powered by its proprietary RITE3™ platform. SEED is advancing a pipeline targeting traditionally undruggable proteins across oncology, neurodegeneration, immunology, and virology. Strategic collaborations with Eli Lilly and Eisai support SEED’s mission to develop transformational therapies. SEED’s lead RBM39 degrader program has cleared US FDA IND. Learn more at seedtherapeutics.com. Cautionary Note Regarding Forward-Looking StatementsThis press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet the Company’s expectations regarding the potential safety, the ultimate efficacy or clinical utility of the Company’s product candidates, increased competition in the market, the Company’s ability to meet Nasdaq’s continued listing requirements, and other risks described in BeyondSpring’s most recent Form 10-K on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law ContactsInvestor Relations: ir@beyondspring.comMedia: pr@beyondspringpharma.com Financial Tables to Follow BEYONDSPRING INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data) As of December 31, 2024 June 30, 2025 (Unaudited) Assets Current assets: Cash and cash equivalents 2,922 9,544 Advances to suppliers 240 255 Prepaid expenses and other current assets 68 200 Current assets of discontinued operations 25,347 15,712 Total current assets 28,577 25,711 Noncurrent assets: Property and equipment, net 239 202 Operating right-of-use assets 513 431 Other noncurrent assets 213 216 Noncurrent assets of discontinued operations 4,773 4,483 Total noncurrent assets 5,738 5,332 Total assets 34,315 31,043 Liabilities and equity Current liabilities: Accounts payable 295 266 Accrued expenses 840 926 Current portion of operating lease liabilities 282 307 Other current liabilities 780 612 Current liabilities of discontinued operations 8,813 9,619 Total current liabilities 11,010 11,730 Noncurrent liabilities: Operating lease liabilities 307 170 Deferred revenue 27,400 27,919 Other noncurrent liabilities 3,686 3,783 Noncurrent liabilities of discontinued operations 6,197 4,986 Total noncurrent liabilities 37,590 36,858 Total liabilities 48,600 48,588 Commitments and contingencies Shareholders’ deficit Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 40,316,320 and 40,322,320 shares issued and outstanding as of December 31, 2024 and June 30, 2025, respectively) 4 4 Additional paid-in capital 373,185 373,515 Accumulated deficit (407,425) (404,754)Accumulated other comprehensive income 1,336 1,019 Total BeyondSpring Inc.’s shareholders’ deficit (32,900) (30,216)Noncontrolling interests 18,615 12,671 Total shareholders’ deficit (14,285) (17,545) Total liabilities and shareholders’ deficit 34,315 31,043 BEYONDSPRING INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)(Unaudited) Three months ended June 30, Six months ended June 30, 2024 2025 2024 2025 $ $ $ $ Revenue - - - - Operating expenses Research and development (829) (1,002) (1,550) (1,876)General and administrative (1,812) (947) (3,146) (2,683) Loss from operations (2,641) (1,949) (4,696) (4,559)Foreign exchange gain (loss), net (22) 47 (83) 76 Interest income 11 28 40 45 Other income, net 1 18 8 18 Loss before income tax (2,651) (1,856) (4,731) (4,420)Income tax expenses - (22) - (42) Net loss from continuing operations (2,651) (1,878) (4,731) (4,462) Discontinued operations Loss from discontinued operations (1,438) (2,771) (2,646) (6,003)Gain on sale of subsidiary interests - - - 6,986 Income tax expenses - - - - Net income (loss) from discontinued operations (1,438) (2,771) (2,646) 983 Net loss (4,089) (4,649) (7,377) (3,479)Less: Net loss attributable to noncontrolling interests from continuing operations (58) (72) (115) (147)Less: Net loss attributable to noncontrolling interests from discontinued operations - (2,771) - (6,003)Net income (loss) attributable to BeyondSpring Inc. (4,031) (1,806) (7,262) 2,671 Earnings (loss) per share, basic and diluted Continuing operations (0.07) (0.04) (0.12) (0.11)Discontinued operations (0.03) - (0.07) 0.18 Basic and diluted earnings (loss) per share (0.10) (0.04) (0.19) 0.07 Weighted-average shares outstanding Basic and diluted 39,280,607 40,316,320 39,154,885 40,316,320 Other comprehensive loss, net of tax of nil: Foreign currency translation adjustment gain (loss) from continuing operations 165 (343) 587 (494)Foreign currency translation adjustment loss from discontinued operations (3) (27) (11) (34)Comprehensive loss (3,927) (5,019) (6,801) (4,007)Less: Comprehensive income (loss) attributable to noncontrolling interests from continuing operations 1 (194) 97 (324)Less: Comprehensive loss attributable to noncontrolling interests from discontinued operations - (2,798) - (6,037)Comprehensive income (loss) attributable to BeyondSpring Inc. (3,928) (2,027) (6,898) 2,354